"
Team:METU-Gene/Collagen Sponge
From 2009.igem.org
(→The release rate of bioactive hEGF from crosslinking collagen sponges ==) |
(→The release rate of bioactive hEGF from crosslinking collagen sponges ==) |
||
| Line 20: | Line 20: | ||
delivery of rhEGF in bioactive form to stimulate cell | delivery of rhEGF in bioactive form to stimulate cell | ||
proliferation. | proliferation. | ||
| + | |||
| + | <br>In addition, EGF can inhibit gastric | ||
| + | acid secretions in the stomach, enhance the proliferation | ||
| + | and keratinization of epithelial tissues and | ||
| + | accelerate wound healing. Due to its wound healing | ||
| + | properties, EGF is an attractive candidate for a therapeutic | ||
| + | drug. Studies have demonstrated that topical applications | ||
| + | of EGF promote wound healing in healthy and impaired | ||
| + | healing animals. | ||
| + | |||
| + | <br>Since Carpenter and co-workers | ||
| + | first reported that for a mitogenic effect of EGF, a continuous | ||
| + | exposure of the target cells to EGF was required for | ||
| + | a minimum of 6–12 h, maintaining an effective topical | ||
| + | concentration at the wound site for a certain period of time | ||
| + | has become vital in the application of EGF. Indeed, we increased this continuous exposures by using Quaroum Sensing Mechanism of E.coli. | ||
Revision as of 10:31, 13 October 2009
The release rate of bioactive hEGF from crosslinking collagen sponges ==
The purpose of this study was to prepare
recombinant human epidermal growth factor (rhEGF)
collagen sponges for topical applications and investigate
the effects of different types of crosslinked collagen
sponges as platforms for the controlled release of rhEGF.
The microstructure and the drug release rates of collagen
sponges were modified through treatment with different
types (glutaraldehyde (GTA), genipin and 1-ethyl-3-
(3-dimethylaminopropyl)carbodiimide (EDC)), different
concentrations of crosslinking agents and various preparation
conditions.
a good correlation was obtained for
in vitro release rates of rhEGF using the power model. The
crosslinked rhEGF collagen sponges showed a successful
delivery of rhEGF in bioactive form to stimulate cell
proliferation.
In addition, EGF can inhibit gastric
acid secretions in the stomach, enhance the proliferation
and keratinization of epithelial tissues and
accelerate wound healing. Due to its wound healing
properties, EGF is an attractive candidate for a therapeutic
drug. Studies have demonstrated that topical applications
of EGF promote wound healing in healthy and impaired
healing animals.
Since Carpenter and co-workers
first reported that for a mitogenic effect of EGF, a continuous
exposure of the target cells to EGF was required for
a minimum of 6–12 h, maintaining an effective topical
concentration at the wound site for a certain period of time
has become vital in the application of EGF. Indeed, we increased this continuous exposures by using Quaroum Sensing Mechanism of E.coli.
